Marker Therapeutics Inc (MRKR)

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire

GlobeNewswire

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire Inc.

Form 10-Q Marker Therapeutics, For: Mar 31 - StreetInsider.com

StreetInsider.com

Unlocking ferroptosis in prostate cancer — the road to novel therapies and imaging markers - Nature.com

Nature.com

Eliem Therapeutics agrees to acquire Tenet - Pharmaceutical Technology

Pharmaceutical Technology

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 

GlobeNewswire Inc.

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker ... - GlobeNewswire

GlobeNewswire

MRKR Stock Quote Price and Forecast - CNN

CNN

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

GlobeNewswire Inc.

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results - Yahoo Finance

Yahoo Finance

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

GlobeNewswire Inc.

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference - GlobeNewswire

GlobeNewswire

Madrigal stock in focus as FDA clears NASH drug (NASDAQ:MDGL) - Seeking Alpha

Seeking Alpha

Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors - Zacks Investment Research

Zacks Investment Research

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

GlobeNewswire Inc.

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

GlobeNewswire Inc.

NightHawk Changes Name To Scorpius Holdings - Contract Pharma

Contract Pharma

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

GlobeNewswire Inc.

AML cell therapy trials to watch in 2024 targeting GvHD - Clinical Trials Arena

Clinical Trials Arena

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates - GlobeNewswire

GlobeNewswire

Marker Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance - Yahoo Finance

Yahoo Finance

Acute Myeloid Leukemia Market Size and Share to Rise by 2032, Predicts DelveInsight | Key Companies - Chimerix ... - Yahoo Finance

Yahoo Finance

Hematopoietic Stem Cell Transplantation Global Market Report 2023 - Yahoo Finance

Yahoo Finance

Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in ... - GlobeNewswire

GlobeNewswire

Why Motorcar Parts of America Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Tuesday’s - Benzinga

Benzinga

Why Asset Entities Shares Are Trading Higher By 142%? Here Are Other Stocks Moving In Monday’s Mid-Day Se - Benzinga

Benzinga

Top Small-Cap Stocks for June 2023 - Investopedia

Investopedia

A Promising Drug Delivery Method Could Replace Injections with Pills - Lab Manager Magazine

Lab Manager Magazine

Nasdaq Down 100 Points; Advance Auto Parts Earnings Miss Views - Markets Insider

Markets Insider

FDA reviewers raise doubts over data on Sarepta's gene therapy - Reuters

Reuters

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer - GlobeNewswire

GlobeNewswire

Marker to offload cell manufacturing assets to CellReady - Pharmaceutical Technology

Pharmaceutical Technology

7 Low Float Penny Stocks To Watch After SNTG Stock Explodes - Penny Stocks

Penny Stocks

Allogeneic cell therapy approval to pave the way for future therapies in this class - Clinical Trials Arena

Clinical Trials Arena

Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical ... - GlobeNewswire

GlobeNewswire

An Invisible Skin Marker for External Beam Radiation Therapy: Utilization of Ultraviolet Fluorescent Marker Pens - Cureus

Cureus

Cotações de Ações Americanas: Bolsas ao vivo e últimas notícias - Money Times

Money Times

The Top 25 Healthcare Technology Leaders of Los Angeles for 2022 - The Healthcare Technology Report.

The Healthcare Technology Report.

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly ... - Nature.com

Nature.com

Terumo, Eliaz partner to improve outcomes for acute kidney injury - BioWorld Online

BioWorld Online

Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant ... - ScienceDirect.com

ScienceDirect.com

Pancreatic Cancer Pipeline Review | A Drug Pipeline Analysis Report 2021 | DelveInsight - GlobeNewswire

GlobeNewswire

27 Stocks Moving in Friday's Pre-Market Session - Atlantic American (NASDAQ:AAME), Aemetis (NASDAQ:AMTX) - Benzinga

Benzinga

Therapy for Alzheimer's disease: Missing targets and functional markers? - ScienceDirect.com

ScienceDirect.com

Defense Department Plans Study of Covid-19 Blood-Purification Treatment - The Wall Street Journal

The Wall Street Journal

Timing right as Dream Finders Homes IPO hits market | Jax Daily Record - Jacksonville Daily Record

Jacksonville Daily Record

14 Biotech Companies In Houston To Know - Built In

Built In

3 ways Lakewood-based Terumo BCT's products are helping COVID-19 patients - Denver Business Journal - The Business Journals

The Business Journals

FDA grants EUAs for multiple devices that address COVID-19 cytokine storm - BioWorld Online

BioWorld Online

Terumo, Marker Therapeutics get authorisation for blood purification device - Medical Device Network

Medical Device Network